Trial reportCurrent psychiatry reports2007
The STAR*D Project results: a comprehensive review of findings.
Trial report in Current psychiatry reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01047124 (Randomised Control Trial of the Clinical and Cost Effectiveness of a Specialist Expert Mood Disorder Team for Refractory Unipolar Depressive Disorder), which is not on this map. Cited by 263 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomised Control Trial of the Clinical and Cost Effectiveness of a Specialist Expert Mood Disorder Team for Refractory Unipolar Depressive Disorder
Who cites it
263 citing papers in PubMed, 11 syntheses or guidelines pooled it.
- Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression.Translational psychiatry · 2024Pooled it
- Genome-wide association study implicates the role of TBXAS1 in the pathogenesis of depressive symptoms among the Korean population.Translational psychiatry · 2024Pooled it
- Efficacy and tolerability of minocycline in depressive patients with or without treatment-resistant: a meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2023Pooled it
- Exercise improves depression through positive modulation of brain-derived neurotrophic factor (BDNF). A review based on 100 manuscripts over 20 years.Frontiers in physiology · 2023Pooled it
- Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials.Clinical pharmacology and therapeutics · 2022Pooled it
- Efficacy of onabotulinumtoxinA in the treatment of unipolar major depression: Systematic review, meta-analysis and meta-regression analyses of double-blind randomised controlled trials.Journal of psychopharmacology (Oxford, England) · 2021Pooled it
- Economic evaluation in psychiatric pharmacogenomics: a systematic review.The pharmacogenomics journal · 2021Pooled it
- A systematic review of fMRI neurofeedback reporting and effects in clinical populations.NeuroImage. Clinical · 2020Pooled it
- Efficacy of vortioxetine on the physical symptoms of major depressive disorder.Journal of psychopharmacology (Oxford, England) · 2018Pooled it
- Challenges Establishing the Efficacy of Exercise as an Antidepressant Treatment: A Systematic Review and Meta-Analysis of Control Group Responses in Exercise Randomised Controlled Trials.Sports medicine (Auckland, N.Z.) · 2016Pooled it
- Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.Psychological medicine · 2016Pooled it
- Transient frontal spectral events from EEG predict antidepressant response to sertraline in depression.Journal of psychiatric research · 2026Trial
- A pilot study of pharmacogenomic testing as a tool to enhance depression care in Veterans.The pharmacogenomics journal · 2026Trial
- Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm study.Frontiers in pharmacology · 2026Trial
- Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Gender Differences in Psychological Outcomes Following Surf versus Hike Therapy among U.S. Service Members.International journal of environmental research and public health · 2024Trial
- A randomized controlled safety and feasibility trial of floatation-REST in anxious and depressed individuals.PloS one · 2024Trial
- A randomized controlled trial of surf and hike therapy for U.S. active duty service members with major depressive disorder.BMC psychiatry · 2023Trial
- A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance.Clinical and translational science · 2022Trial
- Site-Randomized Controlled Trial of a Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among Youth Living With HIV in the United States.Journal of acquired immune deficiency syndromes (1999) · 2021Trial
203 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The Sequenced Treatment Alternatives to Relieve Depression trial enrolled outpatients with nonpsychotic major depressive disorder treated prospectively in a series of randomized controlled trials. These were conducted in representative primary and psychiatric practices. Remission rates for treatment steps 1 to 4 based on the 16-item Quick Inventory of Depressive Symptomatology-Self-report were 37%, 31%, 14%, and 13%, respectively. There were no differences in remission rates or times to remission among medication switch or among medication augmentation strategies at any treatment level. Participants who required increasing numbers of treatment steps showed greater depressive illness burden and increasingly greater relapse rates in the naturalistic follow-up period (40%-71%). Prognosis was better at all levels for participants who entered follow-up in remission as opposed to those who entered with response without remission. These results highlight the prevalence of treatment-resistant depression and suggest potential benefit for using more vigorous treatments in the earlier steps.
Indexed as
Identifiers
18221624What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.